

### 4.0.3 DOC Cmte minutes

#### **Parkinson's disease guideline committee meeting**

**Date:** 20/07/2015

**Location:** Red Rooms, City Tower, Piccadilly Plaza, M1 4BT

**Minutes:** Final

<b>Committee members present:</b>	
Paul Cooper (Chair)	Present for notes 1-9
Alistair Church (AC)	Present for notes 1-9
Fiona Lindop (FL)	Present for notes 1-9
Ivan Bennett (IB)	Present for notes 1-9
Jane Little (JL)	Present for notes 1-9
Janine Barnes (JB)	Present for notes 1-9
Matthew Sullivan (MS)	Present for notes 5-9
Richard Grunewald (RG)	Present for notes 1-9
Debbie Davies (DD)	Present for notes 1-9
Richard Walker (RW)	Present for notes 1-9
Robin Fackrell (RF)	Present for notes 1-9
Beverly Sheaf (BS)	Present for notes 1-9
Julian Evans (JE)	Present for notes 1-9

<b>In attendance:</b>		
Laura Downey	Technical Analyst	Present for notes 1-9
Stephanie Mills	Project Manager	Present for notes 1-9
Steven Ward	Health Economist	Present for notes 1-9
Susan Spiers	Associate Director	Present for notes 1-9
Louise Picton	Technical Analyst	Present for notes 1-9

### 4.0.3 DOC Cmte minutes

<b>Observers:</b>	
N/A	

<b>Committee member apologies:</b>	
Lynne Osbourne (LO)	
Graham Lennox (GL)	
Paul Shotbolt (PS)	

<b>1, 2, 3 and 4 Welcome to the meeting</b>								
<p>The Chair welcomed the Committee members and attendees to the sixth meeting on Parkinson's disease. The Committee members and attendees introduced themselves.</p> <p>The Chair asked those present to declare any conflicts of interest relevant to the areas being discussed or potential new conflicts.</p> <table border="1"><thead><tr><th>Initials</th><th>Declaration</th><th>Classification</th><th>Chairs action</th></tr></thead><tbody><tr><td>Robin Fackrell (RF)</td><td>Talk given at a UCB meeting but no honorarium received</td><td>Personal non-financial interest</td><td>Declare and participate</td></tr></tbody></table> <p>RF also indicated that he had been asked to Chair a meeting in December but no honoraria would be received. No further conflicts of interest above what had been made known to the NICE team were declared by any other person present.</p> <p>The committee looked over the minutes of the previous meeting and agreed they were an accurate representation of the meeting in June 2015.</p> <p>Laura Downey (LD), Technical Analyst, gave a brief presentation on the NHS England decision to now commission duodopa. LD explained that the guideline would continue with the work currently planned and that the committee would be informed if there was any change of approach to developing the guideline.</p>	Initials	Declaration	Classification	Chairs action	Robin Fackrell (RF)	Talk given at a UCB meeting but no honorarium received	Personal non-financial interest	Declare and participate
Initials	Declaration	Classification	Chairs action					
Robin Fackrell (RF)	Talk given at a UCB meeting but no honorarium received	Personal non-financial interest	Declare and participate					
<b>5. Presentations : RQ11: What is the comparative effectiveness of pharmacological interventions for nocturnal akinesia?</b>								
<p>LD presented evidence on pharmacological interventions for nocturnal akinesia. There was little new evidence since the previous guideline. The Committee debated</p>								

#### 4.0.3 DOC Cmte minutes

the quality of the evidence and considered the benefits and disadvantages of making recommendations on this specific aspect of sleep alone. The group went on to make recommendations.

#### **6. Presentations: RQ8 recap and RQ10: What are the information needs of people with Parkinson's disease and their families and carers about the potential for impulse control disorder (ICD) when considering or starting dopaminergic treatment?**

LD gave a recap on the evidence for the potential predictive factors for the development of an impulse control disorder after finding an additional study that could be included within the review.

LD then went onto present the evidence on the information needs of people with Parkinson's disease and their carers about the potential for impulse control disorders when starting dopaminergic therapy. Very limited evidence was available for the committee to consider. The group debated issues of consent for starting dopaminergic therapy and discussed how serious the impact of problematic impulse control behaviours can be on people with Parkinson's disease and their families. They then went on to make recommendations.

#### **7. Health economics modelling update**

The Chair introduced Steven Ward (SW), Health Economist on the Internal Clinical Guidelines technical team. The Committee were asked for their thoughts on the structure of the health economic model. The group discussed the issues that influence the decision on whether a person with Parkinson's disease enters residential or full time care.

SW updated the group on the information which had been received from stakeholders during the call for evidence.

LD took an opportunity to ask the committee some questions about the clinical evidence which will be prepared to underpin the health economic modelling.

#### **8. Linking evidence to recommendations tables**

The Committee were asked to look at the draft summary of their discussions from earlier in the day, relating to how they had formulated their recommendations.

Laura agreed to complete the writing of the linking evidence to recommendations in full prose so these could be sent out to the committee in the week following the meeting.

#### **9. Summary and next steps**

#### **4.0.3 DOC Cmte minutes**

Stephanie Mills (SM), the guideline Project Manager, thanked the group for their attendance and confirmed the date and location of the next meeting.

**Date of next meeting:** 11/09/2015

**Location of next meeting:** NICE Offices, Manchester